Compass Pathways is trading 5.12% down now at $13.49 after no clear company-specific announcement emerged on August 13, 2026.

  • The August 12 Canaccord conference highlighted COMP360’s potential 2027 launch, but the positive discussion does not explain the decline.
  • Broader markets are higher, making a market-wide cause less convincing.
  • Recent coverage focuses on ongoing FDA progress, cash runway, and prior clinical updates; no fresh negative catalyst has been identified.